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Abstract
Background: Randomised trials have highlighted the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs)
in high doses and sometimes atypical settings. Here, we provide estimates of the comparative risks with individual NSAIDs
at typical doses in community settings.
Methods and Findings: We performed a systematic review of community-based controlled observational studies. We
conducted comprehensive literature searches, extracted adjusted relative risk (RR) estimates, and pooled the estimates for
major cardiovascular events associated with use of individual NSAIDs, in different doses, and in populations with low and
high background risks of cardiovascular events. We also compared individual drugs in pair-wise (within study) analyses,
generating ratios of RRs (RRRs). Thirty case-control studies included 184,946 cardiovascular events, and 21 cohort studies
described outcomes in .2.7 million exposed individuals. Of the extensively studied drugs (ten or more studies), the highest
overall risks were seen with rofecoxib, 1.45 (95% CI 1.33, 1.59), and diclofenac, 1.40 (1.27, 1.55), and the lowest with
ibuprofen, 1.18 (1.11, 1.25), and naproxen, 1.09 (1.02, 1.16). In a sub-set of studies, risk was elevated with low doses of
rofecoxib, 1.37 (1.20, 1.57), celecoxib, 1.26 (1.09, 1.47), and diclofenac, 1.22 (1.12, 1.33), and rose in each case with higher
doses. Ibuprofen risk was seen only with higher doses. Naproxen was risk-neutral at all doses. Of the less studied drugs
etoricoxib, 2.05 (1.45, 2.88), etodolac, 1.55 (1.28, 1.87), and indomethacin, 1.30 (1.19, 1.41), had the highest risks. In pair-wise
comparisons, etoricoxib had a higher RR than ibuprofen, RRR=1.68 (99% CI 1.14, 2.49), and naproxen, RRR=1.75 (1.16, 2.64);
etodolac was not significantly different from naproxen and ibuprofen. Naproxen had a significantly lower risk than
ibuprofen, RRR=0.92 (0.87, 0.99). RR estimates were constant with different background risks for cardiovascular disease and
rose early in the course of treatment.
Conclusions: This review suggests that among widely used NSAIDs, naproxen and low-dose ibuprofen are least likely to
increase cardiovascular risk. Diclofenac in doses available without prescription elevates risk. The data for etoricoxib were
sparse, but in pair-wise comparisons this drug had a significantly higher RR than naproxen or ibuprofen. Indomethacin is an
older, rather toxic drug, and the evidence on cardiovascular risk casts doubt on its continued clinical use.
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The risk of cardiovascular events during treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) has been one of the
most studied adverse drug reactions in history. Concern was
initially evoked by a consideration of basic mechanisms of the
drugs [1]. This was reinforced by signals that emerged in large
clinical trials designed (primarily) to examine gastrointestinal
effects [2,3]. Pharmaco-epidemiological studies have confirmed
and quantified these effects using large linked administrative
databases in several countries [4,5].
In contrast to gastrointestinal complications, where the average
relative risk (RR) was estimated to be around 4, many of the RR
estimates for cardiovascular complications have been in the range
of 1.0 to 2.0 [6,7]. This limits the statistical power to examine
variations in risk within individual studies. But it is important to
know whether risk varies with individual drugs, with dose and
duration of therapy, or according to patient characteristics, such as
underlying cardiovascular risk. There are additional concerns
about the risk associated with non-prescription NSAIDs that are
available in low-dose forms, including ibuprofen, naproxen, and
diclofenac [8].
Exploration of these factors requires systematic review and
meta-analysis of the available studies. Several large systematic
reviews have been published covering randomised trials and non-
randomised pharmaco-epidemiological studies [7,9–12]. These
reviews have highlighted apparent differences between individual
drugs, but have provided limited information on dose effects and
relevant patient characteristics, and have not provided direct
comparisons between drugs on the basis of cardiovascular risk.
Most of the analyses have involved a few extensively investigated
drugs, with little information on some widely available com-
pounds, such as etoricoxib, etodolac, meloxicam, indomethacin
and piroxicam.
Our purpose here is to update our previously published review
of large observational studies in order to provide updated risk
estimates for the most widely studied drugs, those that have been
less commonly investigated, and newer drugs that were not
included in our previous systematic review [7]. We wanted to
obtain comparative estimates of risk for individual drugs and to
investigate the likely effects of non-prescription use through
examination of risk at low doses of relevant drugs, over short
time periods and in low risk populations.
Methods
Overview
We did not develop a new protocol as we followed closely the
methods outlined in an earlier version of this work [7]. We
confined our analysis to non-randomised controlled observational
designs. Placebo-controlled trials of NSAIDs have captured fairly
small numbers of cardiovascular events, which are insufficient to
inform all of the discriminatory analyses we proposed here. In
addition, the available randomised data have been summarised in
recent and on-going meta-analyses [9,10,13].
We used a range of complementary approaches to analyse the
data. The overall results for individual drugs were summarised
acrossstudies aspooled RRestimateswith95% confidenceintervals
(CIs). The numbers of studies contributing to these estimates varied
with individual drugs. For the sub-sets of studies that provided
relevant data, we pooled within-study RR estimates with high and
low doses and in patients at high and low risk of cardiovascular
events. These were pre-specified analyses, and we report the 95%
CIs. To compare individual drugs we carried out pair-wise within-
study analyses. Because of the large number of possible compar-
isons, we calculated 99% CIs around these estimates (see below).
Literature Search and Study Eligibility
Studies were eligible for inclusion if they were controlled (case-
control, case-crossover, or controlled cohort designs) and
reported on cardiovascular risks associated with the current use
of the individual drugs in population settings, with non-use or
remote use as the reference exposure. A librarian, an
experienced Cochrane reviewer, and one of the authors searched
electronic databases for articles published during the period 1
January 1985 to 30 November 2010. The databases included
Medline, Embase, PubMed, Cochrane Library, Google Scholar,
epidemiological research websites, abstracts of scientific meet-
ings, and bibliographies of relevant studies. The search terms
included the generic names of individual drugs, therapeutic
classes and modes of action, cardiovascular and cerebro-vascular
outcome terms, and study design descriptors (Text S1). We also
performed searches using the names of authors known to have
conducted research on cardiovascular and cerebro-vascular risks
associated with NSAID use. We applied no language restrictions.
Titles and abstracts of papers identified by the searches were
reviewed by the authors. Searches were re-run using additional
search terms identified from papers considered relevant to the
review.
Study Exposures and Outcomes
We wished to study exposure to any NSAID, including selective
Cox-2 inhibitors. For the studies included in this analysis, the
NSAID prescription was regarded as being current if it covered a
period that included the index day or continued to within 1 week
or less of the index day (i.e., the day the adverse cardiac event
occurred). The most commonly reported outcome was acute
myocardial infarction; many studies included coronary heart
disease–related death and some reported a composite of
myocardial infarction and coronary heart disease death; a
minority reported on stroke only. Where it was possible to extract
risk estimates for all cardiovascular and cerebro-vascular events
separately, we did so.
Risk of Bias in Individual Studies
The most common adjustment variables used by authors were:
age, sex, vascular risk factors, co-morbidities, and prescribed
medications. These were handled fairly consistently across the
studies. Important factors that were generally not reported as
being adjusted for included non-prescription use of aspirin and
NSAIDs, smoking, alcohol use, and body mass index. Quality
assessment and data extraction were performed in duplicate, with
resolution of any discrepancies by consensus. Methodological
quality was assessed using the Newcastle–Ottawa Scale [14].
Authors contacted to obtain additional details provided the
information requested. Nearly all the studies were conducted
using linkage of large electronic health administration databases or
electronic health records (Table S1). As these have wide
community coverage and document, in real time, data on drug
prescribing or dispensing, and subsequent clinical events, they
minimise selection biases and some measurement biases that affect
classic retrospective case-control designs. Therefore, we felt it
appropriate to combine data from different study designs in order
to improve our ability to discriminate between individual drugs
and drug doses.
Cardiovascular Risks with Individual NSAIDs
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We did not use raw data in the calculations. We extracted the
adjusted risk estimates for individual drugs and for the doses
reported. Where there were several publications that used the
same or overlapping datasets, we extracted the most complete
information on cardiovascular risk associated with different doses
of individual NSAIDs. We pooled the odds, risk, or hazard ratio
estimates for all unique cardiovascular outcomes that represented
the most recent use of a NSAID and had been adjusted for
potential confounders. We extracted point estimates and 95% CIs
in duplicate from each study and combined them using a random
effects model for all the comparisons reported here. We performed
all statistical analyses in Stats Direct (version 2.7.8). Forest plots
were generated using Review Manager (version 5).
Heterogeneity was assessed by the Cochran Q and I
2 statistics.
Our purpose in this study was to explain heterogeneity in terms of
factors that were associated with variations in RR, including
individual drugs, dose, background risk of cardiovascular events,
and timing of risk. Our examination of dose effects was restricted
to the published dose cut points as we did not have access to
individual patient data. Where authors had reported them, we
extracted risk estimates for individual drugs measured in
populations considered to be at ‘‘high’’ or ‘‘low’’ background risk
of cardiovascular events (Table S1). We used the authors’
categorisations of risk. The analyses of dose and baseline risk
were performed using within-study data. We also extracted risk
estimates categorised by duration of exposure, recognising that
administrative databases have limited capacity to discriminate
time periods of less than one month (the duration of a typical
prescription).
We compared paired (within-study) RR values with high and
low doses of drugs and in high and low risk populations, and
report the heterogeneity statistics as a measure of the statistical
significance of any differences. Direct comparisons of overall RR
estimates for individual drugs were potentially confounded at study
level, so we carried out a series of pair-wise comparisons of drugs
that had been included in the same studies. For each pair of drugs,
we compared their RRs for a myocardial infarction by the method
of Altman and Bland [15], using an online tool [15,16]. This
yielded a ratio of RRs (RRR) with its CI. RRRs were pooled using
a random effects model. Because of concerns about multiple
testing, we were selective in making comparisons, and we
calculated 99%, rather than 95%, CIs around the pooled RRR
values. In addition, we chose a threshold p-value for reporting
based on the Bonferroni adjustment for multiple comparisons
(Table 4).
Selecting Pair-Wise Comparisons of Individual Drugs
In view of the large number of potential pair-wise comparisons,
we selected pairs on the basis of the following: (a) the amount of
direct comparative data that was available to enable the analyses
and (b) the most relevant clinical and regulatory questions.
Etoricoxib and etodolac have been little studied. Etoricoxib is not
marketed in North America but is widely available elsewhere [17].
Meloxicam is widely used in Australia, where it partially replaced
rofecoxib after its withdrawal [18]. Indomethacin is an older drug
that is still used in the acute treatment of gout [19]. Diclofenac has
been highlighted repeatedly as a cardiovascular risk but has not
been compared directly with other commonly used drugs,
particularly ibuprofen and naproxen, which, like diclofenac, are
available in some countries without prescription [7,8]. We
compared three popular drugs, naproxen, celecoxib, and ibupro-
fen, as these have emerged from most of the reviews as having
lower than average risk, and we wanted to know which was the
safest.
Sensitivity Analyses
Because a number of the pooled RR values were close to one,
we carried out sensitivity analyses to determine the strength of an
association between cardiovascular events and a hypothetical
unmeasured confounder that would be capable of generating the
observed RR, if the true value of the association of interest was
one. We used a method proposed by Schneeweiss [20]. In
calculating these values, we assumed a 15% higher prevalence of
the theoretical confounder in the exposed than in the non-exposed
population. Because of the large number of analyses conducted
here, we limited our sensitivity analyses to the pair-wise
comparisons of the drugs, as these are the most important
measures of relative harm.
Results
The derivation of the database is described in Figure 1. Lists of
included and excluded studies are provided in Text S2. Details of
the included studies, including the characteristics of participants,
and the analytical and adjustment techniques used by study
authors are given in Table S1. The updated database includes 51
studies and 43 unique datasets. Thirty reports of case-control
studies included 184,946 cardiovascular events, and 21 cohort
studies described outcomes in over 2.7 million exposed individuals.
This update more than doubled the amount of statistical
information that was included in previously published systematic
reviews of pharmaco-epidemiological studies [7,12].
We assessed the risk of bias of individual studies using the
Newcastle–Ottawa Scale [14]. Fully reported case-control studies
scored well, 7–8 points from a possible total of 9 points, and cohort
studies scored 7–8 points from a possible total of 10 points. There
was an insufficient range of scores to assess the relationship
between quality and outcome.
Table 1 highlights the variable numbers of studies and
individuals that contributed to the pooled RR estimates for
individual drugs. Table 1 and Figure 2 display the summary
estimates of RR for each drug, with non-use or remote use as the
reference. In Figure 2, the drugs are ranked from highest to lowest
RR, based on the point estimates. It is important to note that some
of the estimates are imprecise, because of sparse data, as reflected
in the wide CIs. Figures 3–13 provide the forest plots from which
the summary estimates were derived. The varying numbers of
studies included in each estimate make comparisons between
drugs difficult because of possible confounding at study level.
Extensively Studied Drugs (Included in Ten or More
Studies)
Of the most studied drugs, rofecoxib and diclofenac had the
highest overall pooled RR values, and naproxen had the lowest
(Figures 3, 6, and 7). Indomethacin was quite close to diclofenac in
terms of risk (Table 1; Figures 7 and 8). All analyses of extensively
studied drugs (except for indomethacin) were statistically hetero-
geneous (Table 1). The variable inclusion of studies in the different
analyses accounts for the apparent discrepancies between overall
RR values given in Table 1 and those given for specific doses, and
in ‘‘high’’ and ‘‘low’’ risk populations, in Tables 2 and 3.
We performed paired analyses of dose effects for five drugs that
had been evaluated in ten or more studies (Table 2). Half of the
studies reporting on rofecoxib provided information on risk with
different doses. For the other drugs, fewer than one-third of studies
reported on dose effects. An apparent increase in risk with dose
Cardiovascular Risks with Individual NSAIDs
PLoS Medicine | www.plosmedicine.org 3 September 2011 | Volume 8 | Issue 9 | e1001098Figure 1. Flow diagram for derivation of studies included in the analyses.
doi:10.1371/journal.pmed.1001098.g001
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statistically significant for rofecoxib, diclofenac, and ibuprofen, but
not for celecoxib. At higher dose levels, there was a doubling or
more in risk with rofecoxib and diclofenac. Importantly, of the
three drugs available without prescription, ibuprofen and
naproxen appeared free of risk at lower doses, in contrast to
diclofenac, which was associated with a statistically significant 22%
increase in risk at low doses (Table 2). Naproxen was not
associated with an increased risk at higher doses, whereas
ibuprofen was.
The doses used as cut points are summarised in the footnote to
Table 2. In the case of rofecoxib and celecoxib, authors were
consistent in reporting doses; increased risks were seen at low doses
of both (# 25 mg and # 200mg/d, respectively). The majority of
studies of ibuprofen defined high doses as more than 1,200 mg/d,
above which the drug increased cardiovascular risk by a relative
78%. In the case of diclofenac, the majority of studies used
100 mg/d as the cut point for analysis, above which the drug
doubled the risk of cardiovascular events. Though indomethacin
was examined in 14 studies, only two reported dose effects, and
they used different cut points for analysis, so data pooling was not
undertaken.
We categorised studies as including ‘‘high risk’’ or ‘‘low risk’’
individuals based on the risk definitions of the individual studies
(Table S1). In general, high risk individuals had experienced prior
vascular ischemic events, while low risk individuals had no such
history. We were able to obtain paired estimates from low and
high risk populations, as outlined in Table 3, which includes the
number of studies that contributed data to each comparison.
There were no systematic differences in the risk estimates
according to background risk of cardiovascular events.
In 12 studies, authors reported events occurring in new users of
NSAIDs. Of seven studies reporting on rofecoxib, five found an
elevated cardiovascular risk within 30 d of commencement. With
celecoxib, risk was evident within 30 d in four of eight studies. In
the case of ibuprofen, risk was elevated within 30 d in three of four
studies, and with diclofenac in three of four studies. Considering
all drugs, nine of 12 studies found cardiovascular risk to be
elevated within the first 30 d of use. In three of these studies, the
risk was reported to be elevated within a median duration of drug
use of 14 d [8,21,22].
Results for Less Extensively Studied Drugs (Included in
Fewer than Ten Studies)
This analysis provided an opportunity to examine some less
studied drugs. Of these, the highest risk was seen with etoricoxib,
investigated in case-control studies only (Table 1; Figure 12). The
numbers of cases and controls contributing data were small.
Despite this, the lower confidence limit, at 1.45, exceeded that for
the other drugs. Valdecoxib was investigated in cohort studies
only; a total of 375 events occurred during 12,391 person-years of
exposure (Table 1; Figure 13). This drug was not associated with
increased risk of cardiovascular events. Etodolac was studied more
Figure 2. Summary analyses for individual drugs. Vertical axis
indicates pooled RR.
doi:10.1371/journal.pmed.1001098.g002
Table 1. Summary of the numbers of studies and overall results.
Drug Case-Control Studies Cohort Studies
Total
Number
of Studies
Pooled RR
(95% CI) Heterogeneity
Number
of Studies
Number of
Exposed Cases/
Controls
Number
of Studies
Number of
Person-Years
of Exposure
Cochran
Qp -Value I
2
Naproxen 24 3,103/24,468 17 159,824 41 1.09 (1.02, 1.16) 143.1 ,0.0001 70.70%
Ibuprofen 21 5,716/37,207 17 255,621 38 1.18 (1.11, 1.25) 226.7 ,0.0001 81.90%
Celecoxib 20 1,496/12,755 15 179,479 35 1.17 (1.08, 1.27) 236.9 ,0.0001 84.40%
Rofecoxib 19 1,662/10,827 15 126,219 34 1.45 (1.33, 1.59) 227.8 ,0.0001 84.20%
Diclofenac 16 3,181/13,523 13 50,736 29 1.40 (1.27, 1.55) 224.4 ,0.0001 86.60%
Indomethacin 11 788/4,406 3 9,350 14 1.30 (1.19, 1.41) 20.8 0.1 32.60%
Piroxicam 7 288/1,216 1 0
a 8 1.08 (0.91, 1.30) 8.6 0.3 18.90%
Meloxicam 6 240/714 1 0
a 7 1.20 (1.07, 1.33) 2.8 0.7 0%
Etodolac 4 464/4,115 1 8,994 5 1.55 (1.28, 1.87) 18.9 0.01 57.70%
Etoricoxib 4 60/116 0 0 4 2.05 (1.45, 2.88) 0.7 0.9 0%
Valdecoxib 1 2/2 4 5,629 5 1.05 (0.81, 1.36) 13.4 0.004 77.60%
aStudies reporting adjusted risk estimates did not all report person-years of exposure.
doi:10.1371/journal.pmed.1001098.t001
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infarction; 2007c, low risk stroke; 2007d, average risk stroke. Andersohn: 2006a, myocardial infarction, cardiovascular death; 2006b, non-fatal stroke.
Fosbol: 2010a, myocardial infarction, cardiovascular death; 2010b, fatal, non-fatal stroke. Gislason: 2006a, recurrent myocardial infarction; 2006b,
death. Gislason: 2009a, myocardial infarction; 2009b, death. Lee: 2007a, low risk cardiovascular event; 2007b, high risk cardiovascular event. Roumie:
2008/09a, low risk cardiovascular event; 2008/09b, high risk cardiovascular event.
doi:10.1371/journal.pmed.1001098.g003
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similar to that of rofecoxib (Table 1; Figure 2). Meloxicam and
piroxicam were not widely investigated (Figures 9 and 10). In the
pooled analyses, meloxicam had a risk profile similar to that of
ibuprofen and celecoxib, while piroxicam appeared similar to
naproxen.
Pair-Wise Comparisons
The results of the pair-wise comparisons are shown in Table 4.
Etoricoxib had a significantly higher RR than either ibuprofen or
naproxen; the point estimates for the RRs suggest it also had a
higher risk than either rofecoxib or diclofenac, but this was not
statistically significant at a p-value of 0.01. More data were
Figure 4. Forest plot for ibuprofen.
doi:10.1371/journal.pmed.1001098.g004
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unpaired comparisons, it was indistinguishable from diclofenac,
naproxen, and ibuprofen in pair-wise comparisons.
Because of growing concerns about risk with diclofenac, we
performed several comparisons. It had a risk identical to that of
rofecoxib and had a significantly higher RR than celecoxib,
naproxen, or ibuprofen.
We thought it was clinically relevant to determine whether naproxen
had any advantage over two other allegedly low risk drugs, celecoxib
and ibuprofen. The summary data show a small but statistically
significant advantage of naproxen over ibuprofen. In contrast, the
overall risks with naproxen and celecoxib appear very similar.
We also performed pair-wise comparisons of less well studied
drugs. The RR with meloxicam was about 10% higher than with
Figure 5. Forest plot for celecoxib.
doi:10.1371/journal.pmed.1001098.g005
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the Bonferroni-adjusted threshold (Table 4). In contrast, indo-
methacin had a statistically significant 23% increase in RR
compared with naproxen.
Sensitivity Analyses
The results of the sensitivity analyses for the pair-wise comparisons
are given in Table 5. With the exception of the comparison between
diclofenac and ibuprofen, a hypothetical unmeasured confounding
variable would need to have an association with the outcome with a
RR of 2.0 or greater (or its reciprocal, 0.5) in order to bias a true null
result to the observed.
Discussion
This updated systematic review of pharmaco-epidemiological
studies of the cardiovascular risks of NSAIDs correlates broadly
Figure 6. Forest plot for rofecoxib.
doi:10.1371/journal.pmed.1001098.g006
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It contributes new information on some familiar drugs, and
provides potentially important information on some little studied
agents.
Commonly Studied Drugs
The highest overall risks were seen with rofecoxib and
diclofenac and the lowest with ibuprofen and naproxen. Naproxen
was risk-neutral at all doses and had a significantly lower RR than
ibuprofen in a pair-wise comparison. Evaluation of dose effects
with rofecoxib, celecoxib, diclofenac, ibuprofen, and naproxen,
and the results of the pair-wise analyses, enabled a more
comprehensive assessment of the comparative risk of these popular
medications. The last three are available without prescription, and
the implications of this are discussed below. In the dose analyses,
the similarity between rofecoxib and diclofenac persisted, and in
neither case did the data define a ‘‘safe’’ lower dose. Celecoxib had
an elevated risk overall and at both low (#200 mg/d) and high
doses (.200 mg/d); data for doses in excess of 200 mg/d were
sparse in these pharmaco-epidemiological studies. However, meta-
analyses of the results of randomised controlled trials have shown a
clear and substantial increase in risk at daily doses of 400 mg or
more [23,24].
The data here suggest that naproxen is superior to ibuprofen in
terms of cardiovascular safety. The apparent safety of naproxen is
well reported, but to our knowledge this is the first evidence to
show a significant difference between these two drugs. A recently
published network meta-analysis of randomised trials also found
naproxen to be the safest choice, and found higher levels of risk
with ibuprofen, particularly for stroke [10]. However, just two
Figure 7. Forest plot for diclofenac.
doi:10.1371/journal.pmed.1001098.g007
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used (2,400 mg/d), and there were only 45 cardiovascular events
among users [10]. As we showed here, dose is critical with
ibuprofen but apparently not with naproxen.
In the pair-wise analyses, celecoxib was indistinguishable from
naproxen. Nevertheless, in the overall analyses, and in the
investigations of dose, it was associated with statistically significant
risk increases. The advantage of naproxen over ibuprofen and
celecoxib is small and must be balanced with its gastrointestinal
risks [6]. However, in our view, it remains the safest choice when
NSAIDs need to be used in patients at high risk of cardiovascular
events. In making this statement we are taking account of the
overall pooled RR value, the lack of a dose-response relationship,
naproxen’s superiority in the pair-wise comparisons, and the
consistency of these findings with its pharmacology—having high
inhibitory activity for Cox-1.
Less Commonly Studied Drugs
Data were sparse for etoricoxib. It is similar in its chemical
structure and pharmacology to rofecoxib; it had a higher RR for
cardiovascular events than ibuprofen and naproxen in pair-wise
comparisons, and had a non-significantly greater RR value than
Figure 8. Forest plot for indomethacin.
doi:10.1371/journal.pmed.1001098.g008
Figure 9. Forest plot for piroxicam.
doi:10.1371/journal.pmed.1001098.g009
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MEDAL randomised trial program, which found similar levels of
cardiovascular risk with etoricoxib and diclofenac [25]. A network
meta-analysis of randomised trials also found etoricoxib to have
the highest RR of cardiovascular death, but did not find an
increased risk of myocardial infarction, stroke, or a composite
cardiovascular outcome [10]. Our analyses were based on small
numbers of events (Table 1), and we are unable to resolve this
apparent contradiction.
Valdecoxib, like etoricoxib, is a highly Cox-2-selective agent,
which was withdrawn from the market in 2005 after excessive
numbers of cardiovascular events were reported among post-
operative cardiac surgery patients [26]. In this meta-analysis, it
was not associated with increased overall risk. The contributing
studies were undertaken among two populations that included
Medicare and Medicaid patients in the United States (see
references A37, A38, A45, and A46 in Text S2). While both
populations had underlying cardiovascular risks, a review of event
rates among different sub-groups showed valdecoxib was compa-
rable with other agents (see reference A38 in Text S2). We are not
able to resolve the apparent discrepancy between randomised and
non-randomised data, which may be due to the play of chance.
This review provides information on four drugs that were not
included in previous meta-analyses of randomised trial data [9–11]
and have been little studied in relation to their cardiovascular
safety: piroxicam, etodolac, indomethacin, and meloxicam.
Piroxicam is similar to naproxen in being a selective inhibitor of
Cox-1 [27]. In these analyses it had a cardiovascular risk profile
similar to that of naproxen. However, its use in recent years has
declined because of concerns about the very high risk of serious
gastrointestinal events [6]. It is hard to believe that the data
reviewed here will reverse its declining market share.
Etodolac was studied more extensively and in the unpaired
analyses had a risk profile similar to that of rofecoxib. However,
the pair-wise analyses are likely to be less confounded, and these
analyses showed etodolac to be similar to two low risk drugs,
ibuprofen and naproxen.
Indomethacin appears to have a risk profile similar to that of
diclofenac in both unpaired and pair-wise analyses and is
associated with a high risk of gastrointestinal damage, as well as
Figure 10. Forest plot for meloxicam.
doi:10.1371/journal.pmed.1001098.g010
Figure 11. Forest plot for etodolac.
doi:10.1371/journal.pmed.1001098.g011
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commonly recommended in the treatment of gout, but there
appear to be no good reasons to retain it in clinical practice.
The data on meloxicam are sparse; although it had a higher RR
than naproxen in the pair-wise analysis, this difference was not
statistically significant. However, the p-value for this comparison,
although not meeting the Bonferroni-adjusted threshold, was close
to 0.01. In other respects, meloxicam appears similar to ibuprofen
and celecoxib, and probably has a level of risk of serious
gastrointestinal events similar to that of diclofenac [30]. However,
taking account of its relative Cox-2 selectivity and the data
presented here, we believe that it should be avoided in patients at
high risk of cardiovascular events.
Importance of Background Risk
The balance of the evidence from the pharmaco-epidemiolog-
ical data summarised here suggests that background risk of
cardiovascular events does not modify the RR in users of these
drugs. In other words ‘‘low risk’’ individuals are exposed to the
same proportional increase in the probability of an adverse event
as those at high background risk, but their excess risk will be lower.
The significance of this finding in relation to potential channelling
effects on cardiovascular risk is discussed below. These findings are
at odds with the results of an individual patient meta-analysis of
randomised placebo-controlled trials of celecoxib [23], which
found that both absolute risk and RR increased with background
risk of cardiovascular disease. This was based on an analysis of
high doses of celecoxib, and there were only 52 events in the
exposed groups.
Timing of Increase in Risk on Treatment
Duration of use was difficult to study because administrative
datasets include information on prescribing or dispensing, not
consumption, of drugs. Accordingly, few studies quantified risk
with duration of use of less than one month. This review
confirmed increases in risk within the first month of treatment for
some of the drugs reviewed here. This conclusion is supported by
an evaluation of the duration of NSAID treatment and associated
cardiovascular risk among a Danish cohort of patients with prior
myocardial infarction [31], which was published after the
completion of our literature review. Treatment with NSAIDs
was associated with early risk of recurrent infarction or death; risk
with rofecoxib was increased after 7–14 d of treatment, with
celecoxib after 14–30 d, and with ibuprofen after 7 d. Diclofenac
increased risk from the beginning of treatment and had the highest
risk, with a hazard ratio of 3.26 (95% CI 2.57, 3.86). Early onset of
risk with NSAIDs is further supported by randomised studies that
have reported increases in risk after brief exposure, and by the
short time course of the biological mechanisms thought to be the
cause of this adverse event [32,33].
Estimating the Effects of Non-Prescription Use of NSAIDs
In considering the risk associated with non-prescription use of
NSAIDs, it is important to consider three factors: safety at low
doses, with short durations of treatment, and in populations with a
low background risk of cardiovascular events. The maximum
recommended daily doses for non-prescription use in the United
Kingdom, as an example, are as follows: ibuprofen, 1,200 mg/d;
naproxen, 750 mg/d; and diclofenac, 75 mg/d. Our risk estimates
Figure 12. Forest plot for etoricoxib.
doi:10.1371/journal.pmed.1001098.g012
Figure 13. Forest plot for valdecoxib.
doi:10.1371/journal.pmed.1001098.g013
Cardiovascular Risks with Individual NSAIDs
PLoS Medicine | www.plosmedicine.org 13 September 2011 | Volume 8 | Issue 9 | e1001098are based on prescription data, not a survey of non-prescription
drug users, and the variable dose cut points used by authors made
interpretation of dose effects difficult. But 1,200 mg/d or less of
ibuprofen appears to be free of risk in the data shown here, and the
cardiovascular risk with naproxen was not significantly elevated
with high or low doses. In contrast, the lower prescription doses of
diclofenac, which were associated with increased risk, fall close to
the maximum daily recommended dose for non-prescription use.
Eight of the ten studies that included analyses of low doses of
diclofenac defined these as 100 mg/d or less, a range that is close
to the maximum recommended dose for non-prescription
diclofenac products (75 mg). The higher doses of ibuprofen (with
higher risk) may be reached relatively easily, particularly with the
400-mg strength preparations that are available without prescrip-
tion in some countries.
Limitations of the Work
There are a number of limitations to this work. We relied on
observational studies, which are subject to a range of biases.
Quantitatively, many of the differences in RR between individual
drugs were small and in a range that might be explained by
residual confounding. However, sensitivity analyses showed that
the majority of the significant pair-wise comparisons were fairly
robust. The exception was the comparison of diclofenac and
ibuprofen. We did not have access to the individual patient data
and were therefore limited to the adjustment procedures used by
the investigators. However, we believe that a high degree of
confounding by indication is unlikely with these drugs, as they are
used in very similar circumstances, there are clear dose effects for
most drugs, and we adjusted for confounding at study level by
performing some key pair-wise within-study analyses. Also, the
ranking of risks correlates fairly closely with what has been seen in
meta-analyses of randomised trials [9,10,23,24]. It is known that
there is a degree of channelling of non-steroidal anti-inflammatory
agents, meaning drugs that have a lower risk of gastrointestinal
adverse effects, such as rofecoxib and celecoxib, may have been
prescribed preferentially to those patients perceived to be at high
risk of this complication [34]. There is a correlation between risk
factors for gastrointestinal and cardiovascular complications.
Although these factors will increase the background risk of
cardiovascular events, and the excess risk attributable to the
drugs, as shown here, they do not appear to influence the RRs.
Most of the studies included here relied on definitions of
exposure and outcomes derived from large linked administrative
databases or electronic health records. Neither source type is
designed for research, and key information, particularly use of
non-prescription NSAIDs and aspirin, is usually not recorded. In
addition, information on cardiovascular risk factors is limited, as
Table 2. Dose-response relationships for individual drugs included in the analyses.
Information
Reported Rofecoxib Celecoxib Ibuprofen Naproxen Diclofenac
#25 mg/d .25 mg/d #200 mg/d .200 mg/d Low High Low High Low High
Overall summary
estimates
1.37 2.17 1.26 1.69 1.05 1.78 0.97 1.05 1.22 1.98
95% CI 1.20, 1.57 1.59, 2.97 1.09, 1.47 1.11, 2.57 0.96, 1.15 1.35, 2.34 0.87, 1.08 0.89, 1.24 1.12, 1.33 1.40, 2.82
p-Value for
dose effect
0.008 0.197 0.0004 0.433 0.009
Studies contributing
dose data
16 of 34 studies
reporting on rofecoxib
11 of 35 studies
reporting on celecoxib
11 of 38 studies reporting
on ibuprofen
10 of 41 studies reporting
on naproxen
10 of 29 studies
reporting on diclofenac
Heterogeneity
Cochrane Q
71.8 80.7 33.7 119.9 43.3 221.4 11.7 29.4 16.3 437.5
p-Value ,0.0001 ,0.0001 0.0008 ,0.0001 ,0.0001 ,0.0001 0.4 0.0058 0.1786 ,0.0001
The RR values in this table differ from those in Table 1 because only a sub-set of all available studies reported dose-response relationships. ‘‘Low’’ and ‘‘high’’ daily doses
of ibuprofen, naproxen, and diclofenac were defined in the individual studies as follows. Ibuprofen low dose/high dose: eight studies, #1,200 mg/.1,200 mg; one
study, #1,600 mg/.1,600 mg; two studies, ,1,800 mg/$1,800 mg. Naproxen low dose/high dose: two studies, #500 mg/.500 mg; four studies, #750 mg/
.750 mg; four studies, #1,000 mg/$1,000 mg. Diclofenac low dose/high dose: six studies, #100 mg/.100 mg; two, studies ,100 mg/$100 mg; two studies,
,150 mg/$150 mg.
doi:10.1371/journal.pmed.1001098.t002
Table 3. Estimated RRs of cardiovascular events according to risk of cardiovascular disease.
Information Reported Drug
Rofecoxib Celecoxib Ibuprofen Naproxen Diclofenac
Low risk population 1.49 (1.28, 1.75) 1.16 (1.02, 1.31) 1.15 (0.99, 1.33) 1.29 (1.09, 1.46) 1.19 (1.07, 1.32)
High risk population 1.54 (1.28, 1.84) 1.17 (1.04, 1.31) 1.32 (1.10, 1.57) 1.23 (1.00, 1.50) 1.14 (0.99, 1.30)
p-Value for difference between RR estimates 0.787 0.921 0.242 0.709 0.625
Number of studies contributing data 11 11 6 9 6
Data are given as pooled RR (95% CI). Analyses are from studies that made paired comparisons of cardiovascular risk with individual drugs in low and high risk
populations; the definitions of these populations are given in the text, and individual studies are described in Table S1. The RR values in this table differ from those in
Table 1 because only a sub-set of all available studies provided data to assess the relationship between RR and background risk of cardiovascular events.
doi:10.1371/journal.pmed.1001098.t003
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tests are generally not included in the databases. The adjustments
made in these studies relied on other measures, such as a history of
cardiovascular events and prescriptions written for diabetes,
hypertension, and hyperlipidaemia.
Heterogeneity was very significant in many of the analyses we
conducted. We looked extensively for causes of heterogeneity, by
studying variation in RR with dose, background risk, and year of
publication (data not shown). Within these sub-group analyses,
heterogeneity was common. The most important association with
heterogeneity was the amount of available statistical information—
heterogeneity was more significant with extensively studied drugs
(Table 1). This may be due to the fact that the individual RR
estimates for these commonly used drugs were very precise, as they
were estimated in large population databases. Consequently,
heterogeneity statistics tended to be significant even though the
differences between the study-specific estimates were small.
While high quality randomised studies provide the least biased
estimates of treatment effects, they are not commonly used to
investigate adverse effects. Meta-analyses of randomised data on
adverse events, preferable in theory to observational data, may be
constrained by small numbers of events [9–11,23,24]. Some
reassurance of the accuracy of observational data is provided by a
recent comparison of estimates of harm from meta-analyses of
randomised studies with those from meta-analyses of observational
studies, which found risk estimates for the events investigated to be
concordant [35]. That analysis included data from the earlier
version of this review.
Conclusions
Despite the limitations of the data, the large sizes of the studies
reviewed here, the presence of consistent dose-response relation-
ships, and general agreement with the results of randomised trials
give us confidence in the results. In our view, the results are
sufficiently robust to inform clinical and regulatory decisions.
From a clinical perspective, naproxen and low-dose ibuprofen
have the most favourable cardiovascular risk profiles. This
advantage has to be weighed against the drugs’ gastrointestinal
risks, and for ibuprofen, avoidance of antagonism of aspirin’s
beneficial effect [36]. While celecoxib was indistinguishable from
naproxen in pair-wise comparisons, the more extensive dose data
available in the randomised trials, and a consideration of its
relative Cox-2 selectivity, makes us reluctant to recommend it in
patients at risk of cardiovascular events. The data for etoricoxib
are limited but raise serious concerns about its safety, particularly
as analogues such as rofecoxib and lumiracoxib have already been
withdrawn. The review supports the calls for regulatory action on
diclofenac, particularly as it is available without prescription in
Table 4. Selected pair-wise comparisons of individual drugs.
Drug Tested Reference Drug in the Comparison
Rofecoxib Diclofenac Ibuprofen Naproxen Celecoxib
Etoricoxib 1.29 (0.86, 1.93),
n=3 studies
1.36 (0.89, 2.09),
n=3 studies
1.68 (1.14, 2.49),
n=3 studies
1.75 (1.16, 2.64),
n=3 studies
Etodolac 0.95 (0.78, 1.16),
n=5 studies
1.04 (0.88, 1.24),
n=7 studies
1.10 (0.96, 1.26),
n=7 studies
Diclofenac 1.0 (0.89, 1.12),
n=18 studies
1.13 (1.03, 1.24),
n=27 studies
1.22 (1.11, 1.35),
n=25 studies
1.15 (1.02, 1.30),
n=19 studies
Naproxen 0.92 (0.87, 0.99),
n=32 studies
__ 0.96 (0.81, 1.13),
n=23 studies
Meloxicam 1.11 (1.0, 1.23),
n=6 studies
Indomethacin 1.23 (1.10, 1.39),
n=15 studies
Values are pooled RRRs and 99% CIs. Bold indicates significant difference at p,0.0033 (the Bonferroni-adjusted threshold p-value; n=15 comparisons; alpha=0.05).
doi:10.1371/journal.pmed.1001098.t004
Table 5. Results of sensitivity analyses on selected pair-wise comparisons.
Comparison RRR RRCD PC1 PC0 RRRadj Percent Bias
Etoricoxib versus naproxen 1.75 11.00 0.25 0.10 1.00 75.00
Etoricoxib versus ibuprofen 1.68 9.40 0.25 0.10 1.00 68.48
Indomethacin versus naproxen 1.23 2.80 0.25 0.10 1.00 22.88
Diclofenac versus naproxen 1.22 2.70 0.25 0.10 1.00 21.79
Diclofenac versus celecoxib 1.15 2.10 0.25 0.10 1.00 14.86
Diclofenac versus ibuprofen 1.13 1.95 0.25 0.10 1.00 13.01
Naproxen versus ibuprofen 0.92 0.50 0.25 0.10 1.00 27.89
RRCD is the association between confounder and disease outcome. PC1is the prevalence of confounder in the exposed. PC0 is the prevalence of confounder in the
unexposed. RRRadj is the ‘‘true’’, or fully adjusted, RRR. Percent bias is the percentage change to the RRR that would be introduced by a hypothetical confounding
variable under the assumptions in the table.
doi:10.1371/journal.pmed.1001098.t005
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doses, unlike its competitor drugs. In the case of ibuprofen,
labelling warnings should be strengthened to stop patients at high
background risk of cardiovascular disease exceeding the maximum
recommended dose for non-prescription use of 1,200 mg/d. The
review also casts doubts on the safety of an older drug,
indomethacin. Indomethacin has a range of gastrointestinal and
central nervous system effects that, combined with the evidence
presented here on cardiovascular risk, should lead to questioning
of its continued clinical use.
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Background. The analgesic (pain relieving), anti-pyretic
(fever reducing), and anti-inflammatory (inflammation
reducing) properties of the class of drug called non-
steroidal anti-inflammatory drugs (NSAIDs)—so called to
distinguish this class of drug from steroids, which have
similar but additional effects—make NSAIDs one of the most
frequently used drugs for the symptomatic treatment of
many common conditions. Some preparations of NSAIDs can
be bought over the counter, and all are available on
prescription, but this class of drug has well documented
side effects and risks: people taking NSAIDs are on average
four times more likely to develop gastrointestinal
complications than people not taking these drugs (that is,
the relative risk of gastrointestinal complications is 4), and
the relative risk for associated cardiovascular
complications—cardiovascular events during treatment
with NSAIDs has been one of the most studied adverse
drug reactions in history—ranges from 1.0 to 2.0.
Why Was This Study Done? Several large systematic
reviews, including one conducted by these researchers, have
previously highlighted apparent differences in cardiovascular
risk between individual drugs, but these reviews have
provided limited information on dose effects and relevant
patient characteristics and have not directly compared the
cardiovascular risks of each drug. Furthermore, most of these
analyses extensively investigated only a few drugs, with little
information on some widely available compounds, such as
etoricoxib, etodolac, meloxicam, indomethacin, and
piroxicam. Therefore, the researchers conducted this study
to update cardiovascular risk estimates for all currently
available NSAIDs and to compare the risks between
individual drugs. In order to investigate the likely effects of
over-the-counter use of NSAIDS, the researchers also wanted
to include in their review an analysis of the cardiovascular
risk at low doses of relevant drugs, over short time periods,
and in low risk populations.
What Did the Researchers Do and Find? The researchers
included only controlled observational studies in their
literature search and review (conducted by searching a
wide range of databases for studies published from 1985
until November 2010) because randomized controlled trials
have reported only small numbers of cardiovascular events
that are insufficient for the purposes of this study. The
researchers assessed the methodological quality of selected
studies, analyzed adjustment variables (for example, age, sex,
other medications), and summarized overall results for
individual drugs across studies as pooled relative risk
estimates. For the subsets of studies that provided relevant
data, they pooled within-study relative risk estimates with
high and low doses and in people at high and low risk of
cardiovascular events, and performed a series of within-study
(pair-wise) comparisons and for each pair of drugs, to
estimate their comparative relative risks by using a validated
online tool to give a ratio of relative risks.
Using this methodology, the researchers included 30 case-
control studies and 21 cohort studies: the highest overall
risks were with rofecoxib and diclofenac, and the lowest risks
were with ibuprofen and naproxen, The researchers found
that risk was elevated with low doses of rofecoxib, celecoxib,
and diclofenac, and rose with higher doses. Ibuprofen risk
was only evident with higher doses. Naproxen did not cause
any additional risks at any dose. Of the less studied NSAIDs,
etoricoxib, etodolac, and indomethacin had the highest risks.
In the pair-wise comparisons, the researchers found that
etoricoxib had a higher relative risk than ibuprofen and
naproxen, etodolac was not significantly different from
naproxen and ibuprofen, and naproxen had a significantly
lower risk than ibuprofen. Finally, the researchers showed
that relative risk estimates were constant with different
background risks for cardiovascular disease and increased
early the course of treatment.
What Do These Findings Mean? This updated systematic
review gives some new information on some familiar NSAIDs,
and provides potentially important information on some
little studied ones, which will help to inform clinical and
regulatory decisions. The specific findings suggest that
among widely used NSAIDs, naproxen and low-dose
ibuprofen are least likely to increase cardiovascular risk,
whereas diclofenac in doses available without prescription
elevates risk. Based on sparse data, etoricoxib has a high risk
of cardiovascular events and is similar to drugs that have
been withdrawn because of safety concerns. Indomethacin is
an older, rather toxic drug, and the new evidence on
cardiovascular risk casts doubt on its continued clinical use.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001098.
N Wikipedia defines and discusses NSAIDs
N The UK National Health Service and MedicineNet have
useful information on NSAIDs that is suitable for patients
N The National Prescribing Service in Australia has a range of
information on the use of NSAIDs
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